Stocks and Investing
Stocks and Investing
Tue, November 9, 2021
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Andrew Galler Initiated (ADCT) at Buy and Held Target at $44 on, Nov 9th, 2021
Andrew Galler of Wolfe Research, Initiated "ADC Therapeutics SA" (ADCT) at Buy and Held Target at $44 on, Nov 9th, 2021.
Andrew has made no other calls on ADCT in the last 4 months.
There are 2 other peers that have a rating on ADCT. Out of the 2 peers that are also analyzing ADCT, 0 agree with Andrew's Rating of Hold.
These are the ratings of the 2 analyists that currently disagree with Andrew
- Kennen MacKay of "RBC Capital" Maintained at Buy with Increased Target to $34 on, Wednesday, November 3rd, 2021
- Matthew Harrison of "Morgan Stanley" Maintained at Buy with Decreased Target to $47 on, Tuesday, September 7th, 2021
Contributing Sources